Molecular Cancer Therapeutics · 2008 · 63 citations · 28 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyCancer Cell SignalingGlioblastomaGlioma RadiotherapyRadiation TherapyCellular ProliferationPhosphoinositide 3-Kinase PathwayPhosphoinositide 3-Kinase SignalingPi3k InhibitorsPi3k SignalingRadiation Therapy CombinationsTherapeutic RadiosensitizationTumor Growth Rate
The phosphoinositide 3'-kinase (PI3K)-mediated signaling pathway plays a key role in fundamental cellular functions important in normal cellular homeostasis and malignant transformation. Deregulated signaling through this pathway contributes to development of gliomas and their resistance to radiation and chemotherapy. Targeting the PI3K signaling pathway has thus emerged as a promising approach to successful treatment of gliomas. We assessed the radiosensitizing potential of four small-molecule inhibitors that differ in their activities against specific isoforms of the PI3K 110-kDa catalytic subunit (p110). p110alpha inhibitors blocked phosphorylation of both protein kinase B/Akt and S6 in all cell lines examined, effectively decreased cellular proliferation, and produced additive cytotoxic effects in combination with radiation therapy. The p110beta inhibitor exhibited limited biochemical effects and failed to decrease cellular proliferation or viability as either a single agent or in combination with radiation or rapamycin. In vivo studies examining the effects of the p110alpha inhibitor in combination with radiation indicated a significant reduction in tumor growth rate induced by the combined treatment compared with each treatment modality alone. This translated into a trend toward prolonged time-to-failure for mice in the combination treatment group. In conclusion, PI3K inhibitors are promising agents in the treatment of glioblastomas, especially when used in combination with ionizing radiation.
28
Specificity and mechanism of action of some commonly used protein kinase inhibitors
Stephen Davies, Helen Reddy, Matilde Caivano et al. · Biochemical Journal · 2000 · 4.1K citations · Full text
Specificity and mechanism of action of some commonly used protein kinase inhibitors
Stephen Davies, Helen Reddy, Matilde Caivano et al. · Biochemical Journal · 2000 · 3.1K citations
PRAS40 Is an Insulin-Regulated Inhibitor of the mTORC1 Protein Kinase
Yasemin Sancak, Carson C. Thoreen, Timothy R. Peterson et al. · Molecular Cell · 2007 · 1.2K citations · Full text
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Zachary A. Knight, Beatriz González, Morri E. Feldman et al. · Cell · 2006 · 1.2K citations · Full text
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Qi-Wen Fan, Zachary A. Knight, David Goldenberg et al. · Cancer Cell · 2006 · 584 citations · Full text
Medicine, Neuroscience, Oncology +10